Federico
Martinón Torres

2025

1. A 28-Year Multicenter Cohort Study of Nontuberculous Mycobacterial Lymphadenitis in Children, Spain

   Emerging Infectious Diseases, Vol. 31, Núm. 3, pp. 536-546

2. A 5-transcript signature for discriminating viral and bacterial etiology in pediatric pneumonia

   iScience, Vol. 28, Núm. 2

3. A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age

   Infectious Diseases and Therapy, Vol. 14, Núm. 2, pp. 463-481

4. A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment

   Nature communications, Vol. 16, Núm. 1, pp. 673

5. A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine

   Vaccine, Vol. 53

6. Corrigendum to “A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)” [Vaccine 41 (2023) 3387–3398, (S0264410X23004280), (10.1016/j.vaccine.2023.04.036)]

   Vaccine

7. Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population

   Expert Review of Pharmacoeconomics and Outcomes Research

8. Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain

   BMC Infectious Diseases, Vol. 25, Núm. 1

9. DNA methylation signatures of severe RSV infection in infants: evidence from non-invasive saliva samples

   Epigenetics and Chromatin , Vol. 18, Núm. 1

10. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 13, Núm. 6, pp. 517-529

11. Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children

    Infectious Diseases and Therapy, Vol. 14, Núm. 5, pp. 991-1010

12. Full 2023–24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study

    The Lancet Infectious Diseases

13. Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study

    The Lancet Microbe, Vol. 6, Núm. 4

14. How to improve pertussis vaccination in pregnancy: a European expert review

    Expert Review of Vaccines, Vol. 24, Núm. 1, pp. 175-182

15. Interferon gene expression declines over time post-COVID infection and in long COVID patients

    Infectious Diseases, Vol. 57, Núm. 1, pp. 35-48

16. Investigación pediátrica en España: desafíos y oportunidades

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 103, Núm. 1

17. Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infections

    The Lancet Infectious Diseases

18. Novedades de las inmunizaciones en la edad pediátrica

    Pediatria Integral

19. Procalcitonin use in febrile children attending European emergency departments: a prospective multicenter study

    BMC Pediatrics, Vol. 25, Núm. 1

20. RSV prevention: public health lessons from the southern hemisphere

    The Lancet Infectious Diseases